



Model List of Essential Medicines

Daclatasvir

| Section | Indications |
|--|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride) | Chronic hepatitis C |

Daclatasvir + sofosbuvir

| Section | Indications |
|--|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 60 mg + 400 mg | Chronic hepatitis C |

Dasabuvir

| Section | Indications |
|--|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 250 mg tablet | Chronic hepatitis C |

Elbasvir + grazoprevir

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 100 mg | Chronic hepatitis C |

Glecaprevir + pibrentasvir

| Section | Indications |
|--|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 20 mg granules Oral > Solid > tablet: 100 mg + 40 mg | Chronic hepatitis C |

Ledipasvir + sofosbuvir

| Section | Indications |
|--|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 90 mg + 400 mg tablet | Chronic hepatitis C |

Ombitasvir + paritaprevir + ritonavir

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet | Chronic hepatitis C |

Pegylated interferon alfa (2a)

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe | Chronic hepatitis C |

Pegylated interferon alfa (2b)

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe | Chronic hepatitis C |

Ravidasvir

| Section | Indications |
|--|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg | Chronic hepatitis C |

Ribavirin

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg | Chronic hepatitis C |

Simeprevir

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 150 mg | Chronic hepatitis C |

Sofosbuvir

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations | Chronic hepatitis C |
| Oral > Solid > tablet: 200 mg; 400 mg | |

Sofosbuvir + velpatasvir

| Section | Indications |
|---|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations | Chronic hepatitis C |
| Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg | |